Kalaris Therapeutics (NASDAQ:KLRS) Upgraded at Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

KLRS has been the topic of several other reports. Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Citizens Jmp started coverage on Kalaris Therapeutics in a research report on Monday, November 3rd. They issued a “market outperform” rating and a $20.00 price target for the company. Finally, Chardan Capital began coverage on Kalaris Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Kalaris Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $14.00.

Kalaris Therapeutics Stock Performance

NASDAQ KLRS opened at $10.00 on Friday. Kalaris Therapeutics has a one year low of $2.14 and a one year high of $12.90. The company has a market capitalization of $187 million, a price-to-earnings ratio of -2.65 and a beta of -0.09. The company’s 50-day simple moving average is $9.22 and its two-hundred day simple moving average is $6.38.

Insider Buying and Selling at Kalaris Therapeutics

In other Kalaris Therapeutics news, Director Srinivas Akkaraju bought 479,847 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were purchased at an average cost of $10.42 per share, for a total transaction of $5,000,005.74. Following the purchase, the director directly owned 1,979,847 shares in the company, valued at $20,630,005.74. This represents a 31.99% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 74.99% of the stock is owned by insiders.

Institutional Investors Weigh In On Kalaris Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp grew its stake in shares of Kalaris Therapeutics by 12.4% during the fourth quarter. State Street Corp now owns 25,410 shares of the company’s stock worth $214,000 after acquiring an additional 2,800 shares during the last quarter. Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kalaris Therapeutics in the 4th quarter valued at approximately $34,000. Barclays PLC acquired a new stake in Kalaris Therapeutics in the 4th quarter worth approximately $51,000. Johnson Financial Group Inc. purchased a new stake in Kalaris Therapeutics during the 3rd quarter worth approximately $58,000. Finally, Keel Point LLC acquired a new position in Kalaris Therapeutics during the 4th quarter valued at approximately $86,000. 66.05% of the stock is currently owned by hedge funds and other institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.